These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 15367461)

  • 1. Thunderclap headache and reversible segmental cerebral vasoconstriction associated with use of oxymetazoline nasal spray.
    Loewen AH; Hudon ME; Hill MD
    CMAJ; 2004 Sep; 171(6):593-4. PubMed ID: 15367461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxymetazoline nasal spray three times daily for four weeks in normal subjects is not associated with rebound congestion or tachyphylaxis.
    Watanabe H; Foo TH; Djazaeri B; Duncombe P; Mackay IS; Durham SR
    Rhinology; 2003 Sep; 41(3):167-74. PubMed ID: 14579657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute coronary syndrome after nasal spray of oxymetazoline.
    Montastruc F; Montastruc G; Taudou MJ; Olivier-Abbal P; Montastruc JL; Bondon-Guitton E
    Chest; 2014 Dec; 146(6):e214-e215. PubMed ID: 25451367
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical images: Afrin-induced central nervous system vasospasm and thunderclap headache.
    Greene RR
    Arthritis Rheum; 2005 Oct; 52(10):3314. PubMed ID: 16200605
    [No Abstract]   [Full Text] [Related]  

  • 5. Branch retinal artery occlusion after excessive use of nasal spray.
    Magargal LE; Sanborn GE; Donoso LA; Gonder JR
    Ann Ophthalmol; 1985 Aug; 17(8):500-1. PubMed ID: 2413795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term use of oxy- and xylometazoline nasal sprays induces rebound swelling, tolerance, and nasal hyperreactivity.
    Graf P
    Rhinology; 1996 Mar; 34(1):9-13. PubMed ID: 8739860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-ST-elevation myocardial infarction with the use of oxymetazoline nasal spray.
    Rajpal S; Morris LA; Akkus NI
    Rev Port Cardiol; 2014 Jan; 33(1):51.e1-4. PubMed ID: 24405558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxymetazoline and hypertensive crisis in a child: can we prevent it?
    Latham GJ; Jardine DS
    Paediatr Anaesth; 2013 Oct; 23(10):952-6. PubMed ID: 23679077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended use of topical nasal decongestants.
    Yoo JK; Seikaly H; Calhoun KH
    Laryngoscope; 1997 Jan; 107(1):40-3. PubMed ID: 9001263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tolerance and effectiveness of oxymetazoline and xylometazoline in treatment of acute rhinitis].
    Dorn M; Hofmann W; Knick E
    HNO; 2003 Oct; 51(10):794-9. PubMed ID: 14523532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are nasal decongestants safer than rhinitis? A case of oxymetazoline-induced syncope.
    Fabi M; Formigari R; Picchio FM
    Cardiol Young; 2009 Dec; 19(6):633-4. PubMed ID: 19775485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ["Of snakes and crocodiles": central side effects of nose drops and facts about rhinitis medicamentosa].
    Bielenberg J
    Kinderkrankenschwester; 2011 Oct; 30(10):406-8. PubMed ID: 22029138
    [No Abstract]   [Full Text] [Related]  

  • 13. Oxymetazoline nasal spray.
    Graf P
    Laryngoscope; 1998 Aug; 108(8 Pt 1):1255. PubMed ID: 9707257
    [No Abstract]   [Full Text] [Related]  

  • 14. The effects of oxymetazoline on lysozyme secretion from the human nasal mucosa.
    Browning S; Housley D; Richards R; Eccles R
    Acta Otolaryngol; 1997 Nov; 117(6):851-5. PubMed ID: 9442826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The observation of the ciliotoxicity of nasal mucosa with nasal decongestant].
    Teng Y; Zhang X; Xu G; Cai Q; Xu J
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2005 Sep; 19(18):824-6. PubMed ID: 16375111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nasal airway resistance after decongestion with a nasal spray or a bellows device.
    Jessen M; Ivarsson A; Malm L
    Rhinology; 1996 Mar; 34(1):28-31. PubMed ID: 8739865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paranasal sinusitis after long-term use of topical nasal decongestants.
    Min YG; Kim HS; Suh SH; Jeon SY; Son YI; Yoon S
    Acta Otolaryngol; 1996 May; 116(3):465-71. PubMed ID: 8790749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ischaemic strokes with reversible vasoconstriction and without thunderclap headache: a variant of the reversible cerebral vasoconstriction syndrome?
    Wolff V; Armspach JP; Lauer V; Rouyer O; Ducros A; Marescaux C; Gény B
    Cerebrovasc Dis; 2015; 39(1):31-8. PubMed ID: 25547150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal corticosteroid and oxymetazoline for chronic rhinitis: a systematic review.
    Neighbors CL; Salvador CF; Zhu B; Camacho M; Tsai P
    J Laryngol Otol; 2022 Jan; 136(1):8-16. PubMed ID: 34702392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of nasal blood flow and airflow in the decongestant response to oxymetazoline.
    Vaidyanathan S; Williamson P; Lipworth B
    Ann Allergy Asthma Immunol; 2012 Feb; 108(2):77-80. PubMed ID: 22289724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.